Glaxo CEO: Consumer health can stand on its own, but don’t expect a quick spinoff

Carly Helfand

Lately, GlaxoSmithKline CEO Andrew Witty has seemed open to splitting off the industry-leading joint venture he formed with Novartis last year. But let Witty be clear: It likely won't happen for a while.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS